Ipsen, BioMérieux Partner on Theranostics Approach to Cancer | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ipsen and BioMérieux today announced a collaboration using a theranostics approach to focus on hormone-dependent cancers.

The two French firms will combine their expertise and resources to co-develop therapeutics and companion diagnostic tests. The collaboration will leverage Ipsen's broad portfolio of compounds and BioMérieux's diagnostic tests and focus on prostate and breast cancers, neuroendocrine tumors, and pituitary tomors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.